MedTrace Logo

Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens

NCT02505243 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 252

Last updated 2020-12-07

No results posted yet for this study

Summary

The aim of this study is to evaluate RBV plasma concentrations when used in combination with newly developed DAA combinations. If possible, its correlations with SVR rates and incidence of anaemia will be assessed in HCV-patients.

Conditions

  • HCV Coinfection
  • Hepatitis C

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • David Burder, PharmdD, PhD · Radboud University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02505243 on ClinicalTrials.gov